Drug intelligence / Profile preview

beclomethasone + formoterol + saccharomyces boulardii + salbutamol

Development stage
Unknown
Lead developer
Chiesi
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Inhalation, Oral, Intranasal
01

Overview

This is a combination product containing four active ingredients: - **Beclomethasone** is an inhaled corticosteroid that reduces inflammation in the airways, helping to prevent and control symptoms of asthma and chronic obstructive pulmonary disease (COPD)[1][2][7]. - **Formoterol** is a long-acting beta-2 adrenergic agonist (LABA) that acts as a bronchodilator, relaxing airway smooth muscle for prolonged periods and providing both maintenance and rapid relief of bronchoconstriction[1][2][6][7]. - **Salbutamol** (also known as albuterol) is a short-acting beta-2 adrenergic agonist used for quick relief of acute bronchospasm by rapidly dilating the airways[2]. - **Saccharomyces boulardii** is a probiotic yeast commonly used to restore or maintain gut flora balance, particularly during or after antibiotic use or gastrointestinal disturbances. The combination aims to provide comprehensive management for respiratory conditions such as asthma or COPD by addressing airway inflammation (beclomethasone), providing both long-term bronchodilation (formoterol) and rapid symptom relief (salbutamol), while also supporting gastrointestinal health with Saccharomyces boulardii. This specific four-drug combination does not appear to be available as a single marketed product; rather, its components are typically administered separately or in dual/triple combinations.

02

Targets

GR (Glucocorticoid receptor)ADRB2 (β2)

Beyond the preview

Go deeper on beclomethasone + formoterol + saccharomyces boulardii + salbutamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on beclomethasone + formoterol + saccharomyces boulardii + salbutamol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call